$11.41
3.16% day before yesterday
Nasdaq, Oct 03, 10:07 pm CET
ISIN
US67576A1007
Symbol
OCUL

Ocular Therapeutix Inc Stock price

$11.41
-1.53 11.82% 1M
+4.41 63.00% 6M
+2.87 33.61% YTD
+2.18 23.62% 1Y
+7.33 179.31% 3Y
+2.99 35.51% 5Y
-3.64 24.19% 10Y
-1.74 13.23% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.35 3.16%
ISIN
US67576A1007
Symbol
OCUL
Industry

Key metrics

Basic
Market capitalization
$2.4b
Enterprise Value
$2.1b
Net debt
positive
Cash
$391.1m
Shares outstanding
172.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
42.7 | 43.2
EV/Sales
37.0 | 37.5
EV/FCF
negative
P/B
7.9
Financial Health
Equity Ratio
68.9%
Return on Equity
-61.4%
ROCE
-55.9%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$56.7m | $56.0m
EBITDA
$-224.2m | $-272.5m
EBIT
$-228.1m | $-269.7m
Net Income
$-216.8m | $-268.6m
Free Cash Flow
$-179.4m
Growth (TTM | estimate)
Revenue
-7.3% | -12.2%
EBITDA
-80.1% | -62.2%
EBIT
-77.9% | -57.0%
Net Income
-56.6% | -38.8%
Free Cash Flow
-98.0%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
-395.7% | -486.8%
EBIT
-402.6%
Net
-382.5% | -480.0%
Free Cash Flow
-316.5%
More
EPS
$-1.3
FCF per Share
$-1.0
Short interest
8.8%
Employees
274
Rev per Employee
$230.0k
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Ocular Therapeutix Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
94%
Hold
6%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
57 57
7% 7%
100%
- Direct Costs 6 6
7% 7%
11%
51 51
9% 9%
89%
- Selling and Administrative Expenses 107 107
20% 20%
189%
- Research and Development Expense 172 172
113% 113%
304%
-224 -224
80% 80%
-396%
- Depreciation and Amortization 3.92 3.92
5% 5%
7%
EBIT (Operating Income) EBIT -228 -228
78% 78%
-403%
Net Profit -217 -217
57% 57%
-383%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
Seeking Alpha
5 days ago
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Analyst/Investor Day September 30, 2025 2:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Nadia Waheed - Chief Medical Officer Jeffrey Heier, - Chief Scientific Officer Namrata Saroj - Chief Business Officer Jay Robins Peter Kaiser - Chief Development Officer William Slattery - Vice President of Investor Relations Confere...
Neutral
GlobeNewsWire
5 days ago
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, be...
Neutral
GlobeNewsWire
5 days ago
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 274
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today